CYBERLIVER LIMITED – Trademark Portfolio
Entity Type: 99
CYBERLIVER LIMITED holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include C + and CIRRHOCARE. The owner is based in Stanmore, Middlesex.
First Floor, Burnells
5 Garland Road
Stanmore, Middlesex HA71NR , GB
Showing of trademarks Trademarks
Trademark Classifications
CYBERLIVER LIMITED's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does CYBERLIVER LIMITED have?
CYBERLIVER LIMITED has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does CYBERLIVER LIMITED file in?
CYBERLIVER LIMITED files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are CYBERLIVER LIMITED's most well-known trademarks?
CYBERLIVER LIMITED's registered trademark portfolio includes well-known marks such as C + and CIRRHOCARE. These are among 2 currently registered trademarks in the portfolio.
What is CYBERLIVER LIMITED's trademark registration success rate?
CYBERLIVER LIMITED has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.